The next generation biopharmaceuticals
Lokon Pharma and Affibody Initiates a Collaboration to Develop Novel Cancer Therapeutics
Uppsala and Solna, Sweden, January 12, 2022. Lokon Pharma AB, a leading biotech company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses, today announced a collaboration with Affibody AB (“Affibody”) to combine oncolytic viruses with Affibody® molecules.
“Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. We already have one virus in clinical development, LOAd703, and we are expanding our pipeline to meet the demand of different types of malignancies” says Dr. Angelica Loskog, the CEO of Lokon Pharma. She adds, “Affibody’s proprietary antibody mimetics are small proteins with high affinity to desired targets and well suited to combine with our LOAd platform viruses. We are excited to initiate this new collaboration aiming to develop a novel treatment regime for selected cancer indications”.
“We are enthusiastic about investigating this potential extension of our Affibody® technology platform by collaborating with leading researchers in the oncolytic virus field”, says Prof. Fredrik Frejd, CSO of Affibody. “The small size of and potential for high affinity makes Affibody® molecules highly interesting tools for a novel treatment regime with adenovirus platforms”.
Lokon Pharma AB is a Swedish biotech company developing the LOAd platform of oncolytic adenoviruses genetically engineered to express immunostimulatory genes in malignant tumors and tumor stroma. LOAd703 (delolimogene mupadenorepvec) is the first clinical candidate from the platform expressing TMZ-CD40L and 4-1BBL, two potent stimulators of dendritic cells as well as T- and NK cells, which play key roles in the induction of immune responses against cancer cells and supporting stroma. Currently, four clinical trials evaluating LOAd703 in patients with advanced pancreatic, biliary, colorectal, and ovarian cancers and malignant melanoma are ongoing.
Further information can be found at: www.lokonpharma.com.
Affibody is a clinical stage biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Affibody AB is a holding of Patricia Industries.
Further information can be found at: www.affibody.com
Affibodys latest Press releases
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report January to March 2020 (May 15, 2020)
- Interim Report January to June 2020 (August 21, 2020)
- Interim Report January to September 2020 (November 13, 2020)
- Year End Report 2020 (February 2021)